2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Colorectal Neoplasms
34
Carcinoma, Non-Small-Cell Lung
26
Breast Neoplasms
26
Lung Neoplasms
24
Colonic Neoplasms
18
Head and Neck Neoplasms
16
Rectal Neoplasms
14
Prostatic Neoplasms
11
Sarcoma
10
Neoplasm Metastasis
9
Pancreatic Neoplasms
8
Neoplasms
7
Mouth Neoplasms
7
Melanoma
7
Esophageal Neoplasms
7
Adenomatous Polyposis Coli
7
Ovarian Neoplasms
6
Glioblastoma
6
Precancerous Conditions
5
Neuroblastoma
5
Liver Neoplasms
5
Central Nervous System Neoplasms
5
Carcinoma
5
Unspecified Adult Solid Tumor, Protocol Specific
4
Triple Negative Breast Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
4
Recurrence
4
Oropharyngeal Neoplasms
4
Laryngeal Neoplasms
4
Hypopharyngeal Neoplasms
4
Interventions
Sirolimus
10
Everolimus
6
Imatinib Mesylate
2
temsirolimus
1
saracatinib
1
nintedanib
1
carbon-11 acetate
1
Valproic Acid
1
Urination
1
Sugars
1
Simvastatin
1
Resveratrol
1
Respiratory Function Tests
1
Phlebotomy
1
Octreotide
1
Loratadine
1
Letrozole
1
Immunoglobulin G
1
Hydroxychloroquine
1
Glutamine
1
Genetic Testing
1
Doxycycline
1
Disulfides
1
Cetuximab
1
Celecoxib
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphangioleiomyomatosis
×
Celecoxib
×
Clear all
NCT02484664
2022-01-20
COLA
Brigham and Women's Hospital
Phase 2
Completed
12 enrolled
11 charts